Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non‐small cell lung cancer (NSCLC) through inhibition of HIF‐1α
Biziotis, Olga‐Demetra, Tsakiridis, Evangelia Evelyn, Ali, Amr, Ahmadi, Elham, Wu, Jianhan, Wang, Simon, Mekhaeil, Bassem, Singh, Kanwaldeep, Menjolian, Gabe, Farrell, Thomas, Abdulkarim, Bassam, Sur, Ranjan K., Mesci, Aruz, Ellis, Peter, Berg, Tobias, Bramson, Jonathan L, Muti, Paola, Steinberg, Gregory R, Tsakiridis, Theodoros
Published in Molecular oncology (01.11.2023)
Published in Molecular oncology (01.11.2023)
Get full text
Journal Article
Combined metformin-salicylate treatment provides improved anti-tumor activity and enhanced radiotherapy response in prostate cancer; drug synergy at clinically relevant doses
Tsakiridis, Evangelia E., Broadfield, Lindsay, Marcinko, Katarina, Biziotis, Olga-Demetra, Ali, Amr, Mekhaeil, Bassem, Ahmadi, Elham, Singh, Kanwaldeep, Mesci, Aruz, Zacharidis, Panayiotis G., Anagnostopoulos, Alexander E., Berg, Tobias, Muti, Paola, Steinberg, Gregory R., Tsakiridis, Theodoros
Published in Translational oncology (01.11.2021)
Published in Translational oncology (01.11.2021)
Get full text
Journal Article
The SGLT2 inhibitor canagliflozin suppresses growth and enhances prostate cancer response to radiotherapy
Ali, Amr, Mekhaeil, Bassem, Biziotis, Olga-Demetra, Tsakiridis, Evangelia E, Ahmadi, Elham, Wu, Jianhan, Wang, Simon, Singh, Kanwaldeep, Menjolian, Gabe, Farrell, Thomas, Mesci, Aruz, Liu, Stanley, Berg, Tobias, Bramson, Jonathan L, Steinberg, Gregory R, Tsakiridis, Theodoros
Published in Communications biology (08.09.2023)
Published in Communications biology (08.09.2023)
Get full text
Journal Article
18F-DCFPyL (PSMA) PET as a radiotherapy response assessment tool in metastatic prostate cancer
Mesci, Aruz, Ahmadi, Elham, Ali, Amr, Gouran-Savadkoohi, Mohammad, Evelyn Tsakiridis, Evangelia, Biziotis, Olga-Demetra, Chow, Tom, Kapoor, Anil, Sur, Monalisa, Steinberg, Gregory R., Liu, Stanley, Zukotynski, Katherine, Tsakiridis, Theodoros
Published in Clinical and translational radiation oncology (01.03.2023)
Published in Clinical and translational radiation oncology (01.03.2023)
Get full text
Journal Article
40 Canagliflozin, a New Anti-Diabetic Agent Targeting Cellular Metabolism, Suppresses Survival and Enhances the Response of Non-Small Cell Lung Cancer (NSCLC) to Radiotherapy
Biziotis, Olga-Demetra, Tsakiridis, Evangelia - Evelyn, Broadfield, Lindsay, Farrell, Thomas, Menjolian, Gabe, Mathurin, Tammy, Mekhaeil, Bassem, Zacharidis, Panagiotis, Muti, Paola, Abdulkarim, Bassam, Steinberg, Gregory, Tsakiridis, Theodoros
Published in Radiotherapy and oncology (01.10.2019)
Published in Radiotherapy and oncology (01.10.2019)
Get full text
Journal Article
167 The New Diabetes Drug Canagliflozin Enhances the Response of Prostate Cancer to Radiotherapy
Mekhaeil, Bassem, Zacharidis, Panagiotis, Tsakiridis, Evelyn, Biziotis, Olga-Demetra, Broadfield, Lindsay, Menjolian, Gabe, Mathurin, Tammy, Farrell, Thomas, Muti, Paola, Liu, Stanley, Steinberg, Gregory, Tsakiridis, Theodoros
Published in Radiotherapy and oncology (01.10.2019)
Published in Radiotherapy and oncology (01.10.2019)
Get full text
Journal Article
18 F-DCFPyL (PSMA) PET as a radiotherapy response assessment tool in metastatic prostate cancer
Mesci, Aruz, Ahmadi, Elham, Ali, Amr, Gouran-Savadkoohi, Mohammad, Evelyn Tsakiridis, Evangelia, Biziotis, Olga-Demetra, Chow, Tom, Kapoor, Anil, Sur, Monalisa, Steinberg, Gregory R, Liu, Stanley, Zukotynski, Katherine, Tsakiridis, Theodoros
Published in Clinical and translational radiation oncology (01.03.2023)
Get full text
Published in Clinical and translational radiation oncology (01.03.2023)
Journal Article